PDL BioPharma (NDAQ:PDLI) announced that it has successfully sold the rights to its transplant drug IV Busulfex to Japan's Otsuka Pharmaceuticals for $200 in cash in deal that will close in the first quarter. The move should lessen the pressure on the drug maker by activist shareholders who have been pushing the company to unlock shareholder value for the past few months.

Busulfex is one of three products that PDL purchased in 2005 for $500 million in an attempt to boost earnings while it developed its own antibody drug through clinical trials. That strategy ended when activist investor Daniel Loeb's Third Point LLC forced CEO Mark McDade from office and demanded an auction of the company instead.

Third Point cashed out recently, but Highland Capital Management has taken the reins and continued to push the company towards a sale. The activist recently commented that Merrill Lynch should be eliminated and replaced by a M&A advisor more suited to their industry. However, with this recent deal completed, perhaps no change will be necessary.

In the end, PDL BioPharma is likely to continue to sell off its assets in an attempt to liquidate and unlock value for shareholders. Whether or not they will find buyers and obtain fair value for the company remains to be seen, but at least one activist investor remains bullish and this recent sale is encouraging!

Related Companies
Genentech Inc. (DNA)
Medarex Inc. (MEDX)
Immunomedics Inc. (IMMU)

Marshall & Ilsley Corporation (NYSE:MI) announced a series of unusual events that will impact its earnings for the most recent quarter and year end. The diversified financial services company revealed a very strong capital position from a spin off amid write downs from the mortgage crisis. So, what does all of this mean in the end?

M&I announced on November 1st that it completed its spin off of Metavante Technologies, which resulted in a one-time $526 million gain and $1.665 billion in cash from the separation. The company plans on using these funds to retire approximately $1 billion worth of bonds in order to lower its borrowing costs over the next three years.

M&I also announced a $195 million write off in its loan portfolios stemming from the bank's reassessment in light of the deteriorating real estate market. The firm's loan loss provision, covering bad loans, could grow to $235 million which is up from $18.3 million in the fourth quarter of last year. Luckily, the firm remains well capitalized after the sale of its technology arm.

"Despite these challenging market conditions, we are fortunate to have one of the strongest capital positions in the industry," said Mark Furlong, president and CEO, Marshall & Ilsley Corporation. "We believe we are well positioned to weather the downturn in the real estate market."

In the end, M&I remains in good shape despite some rather large mortgage-related losses. Whether or not the bank will fully recover remains to be seen, but this is definitely a stock that it worth watching over the next few months!

Related Companies
Fifth Third Bancorp (FITB)
Synovus Financial Corp (SNV)
Wells Fargo & Company (WFC)

Panera Break Co. (NDAQ:PNRA) may face a shakeup after Roy Disney's Shamrock Activist Value Fund set its targets on the restaurant chain. The activist hedge fund demanded that the company declassify its staggered board and separate the chairman and chief executive roles, according to a Schedule 13D filing made with the SEC on Friday.

Shamrock, which owns 5.46 percent of the Panera, also demanded the same voting rights for all of its common stock and suggested that the company add some new board members with "relevant operating experience". The hedge fund also proposed that the company work to increase its compensation plan to provide increased transparency and urged the company to leverage its strong balance sheet to institute a share repurchase.

These initiatives are collectively designed to help the company's stock recover after dropping more than 30 percent so far this year. Separated roles and increased transparency would help the market become more trusting of the company, while a share repurchase of Class A stock would help even out the field for all shareholders.

In the end, these suggestions may increase trust and transparency, but new board members and direction will be needed to turn the company around. However, this stock is definitely one worth watching!

Related Companies
BAB, Inc. (BABB)
Starbucks Corporation (SBUX)
Triarc Companies Inc. (TRY)